B. Riley Reiterates "Buy" Rating for Trevi Therapeutics (NASDAQ:TRVI)

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report)'s stock had its "buy" rating restated by stock analysts at B. Riley in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $20.00 target price on the stock, up from their prior target price of $11.00. B. Riley's price objective would indicate a potential upside of 209.12% from the stock's previous close. B. Riley also issued estimates for Trevi Therapeutics' Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($0.69) EPS, FY2026 earnings at ($0.83) EPS, FY2027 earnings at ($0.95) EPS, FY2028 earnings at ($1.10) EPS and FY2029 earnings at ($1.17) EPS.

TRVI has been the subject of several other reports. Needham & Company LLC decreased their price objective on shares of Trevi Therapeutics from $25.00 to $24.00 and set a "buy" rating for the company in a research report on Wednesday. HC Wainwright reaffirmed a "buy" rating and set a $12.50 price objective on shares of Trevi Therapeutics in a research report on Wednesday. Oppenheimer increased their price objective on Trevi Therapeutics from $12.00 to $20.00 and gave the company an "outperform" rating in a report on Tuesday, March 11th. Raymond James upgraded Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and boosted their target price for the stock from $9.00 to $29.00 in a research note on Monday, March 10th. Finally, D. Boral Capital reiterated a "buy" rating and issued a $21.00 price target on shares of Trevi Therapeutics in a research note on Wednesday. Seven investment analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $17.56.

Remove Ads

Trevi Therapeutics Trading Down 2.1 %

TRVI traded down $0.14 on Wednesday, hitting $6.47. 3,742,537 shares of the company were exchanged, compared to its average volume of 994,524. The firm has a 50-day moving average price of $4.60 and a two-hundred day moving average price of $3.76. Trevi Therapeutics has a twelve month low of $2.30 and a twelve month high of $7.39. The company has a market cap of $497.32 million, a price-to-earnings ratio of -14.70 and a beta of 0.90.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last released its earnings results on Tuesday, March 18th. The company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.12) by $0.01. Equities analysts expect that Trevi Therapeutics will post -0.49 EPS for the current year.

Insider Activity

In related news, insider Farrell Simon sold 81,313 shares of the company's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $6.75, for a total value of $548,862.75. Following the completion of the sale, the insider now owns 76,900 shares in the company, valued at $519,075. This represents a 51.39 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 24.37% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Frazier Life Sciences Management L.P. boosted its stake in shares of Trevi Therapeutics by 44.5% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 10,664,774 shares of the company's stock worth $43,939,000 after buying an additional 3,283,684 shares during the period. Woodline Partners LP lifted its position in Trevi Therapeutics by 429.9% during the 4th quarter. Woodline Partners LP now owns 3,212,597 shares of the company's stock worth $13,236,000 after acquiring an additional 2,606,370 shares during the period. Squarepoint Ops LLC purchased a new position in shares of Trevi Therapeutics in the 4th quarter valued at approximately $58,000. Two Sigma Advisers LP acquired a new position in shares of Trevi Therapeutics in the fourth quarter valued at approximately $66,000. Finally, Two Sigma Investments LP purchased a new stake in shares of Trevi Therapeutics during the fourth quarter worth approximately $560,000. 95.76% of the stock is owned by hedge funds and other institutional investors.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.